90 related articles for article (PubMed ID: 29746725)
1. A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor.
Dennie J; Vandell AG; Inoue S; Gajee R; Pav J; Zhang G; Zamora C; Masuda N; Uchiyama M; Yamada M; Senaldi G
J Clin Pharmacol; 2018 Dec; 58(12):1557-1565. PubMed ID: 29746725
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.
Vandell AG; Inoue S; Dennie J; Nagasawa Y; Gajee R; Pav J; Zhang G; Zamora C; Masuda N; Senaldi G
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439973
[TBL] [Abstract][Full Text] [Related]
3. Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota.
Kumar M; Mathur T; Joshi V; Upadhyay DJ; Inoue SI; Masuda N
Anaerobe; 2018 Jun; 51():120-123. PubMed ID: 29758524
[TBL] [Abstract][Full Text] [Related]
4.
Mathur T; Barman TK; Kumar M; Singh D; Kumar R; Khera MK; Yamada M; Inoue SI; Upadhyay DJ; Masuda N
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439962
[TBL] [Abstract][Full Text] [Related]
5.
Barman TK; Kumar M; Mathur T; Namba E; Singh D; Chaira T; Kurosaka Y; Yamada M; Upadhyay DJ; Masuda N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610202
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria.
Tyrrell KL; Citron DM; Merriam CV; Leoncio E; Goldstein EJC
Anaerobe; 2018 Dec; 54():39-41. PubMed ID: 30096588
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
9. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.
Pfeifer ND; Lo A; Bourdet DL; Colley K; Singh D
Clin Transl Sci; 2021 Nov; 14(6):2556-2565. PubMed ID: 34318597
[TBL] [Abstract][Full Text] [Related]
10. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.
Chandorkar G; Zhan Q; Donovan J; Rege S; Patino H
BMC Pharmacol Toxicol; 2017 Mar; 18(1):24. PubMed ID: 28347318
[TBL] [Abstract][Full Text] [Related]
12. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.
Lomeli BK; Galbraith H; Schettler J; Saviolakis GA; El-Amin W; Osborn B; Ravel J; Hazleton K; Lozupone CA; Evans RJ; Bell SJ; Ochsner UA; Jarvis TC; Baqar S; Janjic N
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685472
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
Matsuno K; Kuroda S; Tanaka S; Nakamichi H; Kagawa T; Koumura E
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):607-614. PubMed ID: 29845723
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
Manitpisitkul P; Mayorga A; Shalayda K; De Meulder M; Romano G; Jun C; Moyer JA
Clin Drug Investig; 2015 Jun; 35(6):353-63. PubMed ID: 25894894
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
Roberts T; Kokai-Kun JF; Coughlin O; Lopez BV; Whalen H; Bristol JA; Hubert S; Longstreth J; Lasseter K; Sliman J
Clin Drug Investig; 2016 Sep; 36(9):725-734. PubMed ID: 27283946
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects.
Matsuno K; Tanaka S; Hashimoto T; Nakamichi H; Kagawa T; Koumura E
J Clin Pharmacol; 2018 Nov; 58(11):1516-1524. PubMed ID: 29733435
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of DS-3801b, a Motilin Receptor Agonist, in Healthy Subjects.
Dennie J; Atiee G; Warren V; Tao B; Morimoto K; Senaldi G
J Clin Pharmacol; 2017 Sep; 57(9):1221-1230. PubMed ID: 28464321
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
Togawa M; Yamaya H; Rodríguez M; Nagashima H
Clin Drug Investig; 2016 Dec; 36(12):1011-1021. PubMed ID: 27498100
[TBL] [Abstract][Full Text] [Related]
20. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.
Ting LS; Praestgaard J; Grunenberg N; Yang JC; Leeds JA; Pertel P
Antimicrob Agents Chemother; 2012 Nov; 56(11):5946-51. PubMed ID: 22964250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
